

## New Zealand standardised oral formulation batch sheet

Rifabutin suspension 20 mg/mL (60 mL)										
Patient's name			Storage condition		In a refrigerator			At room temperature		
NHI				Temperature		2-8°C		≤ 25°C		
Date compounded			Shelf life		30 days			30 days		
Batch number			Recommended storage					May be stored at room temperature if this is more practical and temperatures greater than 25°C are avoided		
Ingredients required	and formula:									
Ingredient	Supplier	Batch number	Expiry date	Star forn	ndard nula	, ,		ispensed y	Checked by	
Rifabutin 150 mg capsules				8 ca	apsules					
Ora-Blend®	Perrigo			to	60 mL					
OR		•	<b>.</b>			l.			l	
Ora-Plus®	Perrigo				30 mL					
Ora-Sweet®	Perrigo				30 mL					
Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted? Yes										
Calculations performed by										
Calculations checked by (pharmacist)										
Area cleared for proc	cleared for processing by									
Instructions to comp	ound suspension	n:								
1. If Ora-Blend®			ra-Plus® and C	ra-Sv	veet® to	form the dilu	ien	t.		
2. Empty the co	2. Empty the contents of the capsules into the mortar.									
3. Add the dilue	3. Add the diluent (Ora-Blend® or prepared diluent) to form a smooth paste.									
4. Gradually ad	4. Gradually add diluent and transfer to the final measuring flask, rinsing mortar well. Mix well.									
5. Make up to f	5. Make up to final volume and mix well.									
6. Label and package product appropriately.										
Labels										
						Lahel	checked by			
Attach product label and auxiliary labels:							Laber checked by			



## New Zealand standardised oral formulation batch sheet

## Rifabutin suspension 20 mg/mL (60 mL)

Final yield		mL		Checked by					
Final appearance of product		Purple suspension.							
Container		Amber plastic mission bottle.							
Compounded by		Name:	Sigi	nature:	Date:				
Final check and product release		Name:	Sigi	nature:	Date:				
Special instructions:									
<ol> <li>Store in a refrigera</li> <li>Shake well before</li> </ol>									
References:									
1. Haslam JL, Egodage KL, Chen Y, et al. <i>Am J Health Syst Pharm</i> , 1999; <b>56</b> (4): 333-6.									
Prepared by	New Zealand Compounding Working Group								
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ								
Hosted by	Pharmaceutical Society of New Zealand Standard Formulations in the Practice Support section of the PSNZ website								
Version number	3.0		Version approval date 17/07/19						
Document review due	01/08/21								

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.